Click Therapeutics and Boehringer Ingelheim Announce Series D Investment and Funding to Advance Commercialization of CT-155
Boehringer Ingelheim and Click Therapeutics today announced a strategic agreement to support the commercialization of CT-155, an investigational prescription digital therapeutic that is being studied for the treatment of the experiential negative symptoms of schizophrenia in adults aged 18 years and older.3 Under the agreement, Boehringer will transfer full product responsibility, including all commercial and marketing […]
Revelation Partners Deepens Secondaries Expertise with Appointment of Jonathan Au as Partner and Jordan Bloom as Associate
Revelation Partners, the largest secondaries investment manager focused solely on private healthcare, today announced the appointment of Jonathan Au as partner and Jordan Bloom as associate. These additions further strengthen the firm’s deep expertise in secondary transactions and reinforce its commitment to delivering creative capital solutions to founders, management teams, and other private healthcare stakeholders. Au […]
The Expanding Role of Secondaries — Takeaways from HPE Miami 2026
The Revelation Partners team was back in South Beach, Miami on March 4-5 for this year’s HPE Miami conference, joining a growing group of private equity investors and advisors gathering to discuss the evolving healthcare investment landscape. While we are sure the setting helps, it is great to see how much the conference has expanded over the past […]
RoundTable Healthcare Partners Invests in Colorescience, a Premium Skincare and Sun Protection Brand
RoundTable Healthcare Partners (“RoundTable”), an operating-oriented private equity firm focused exclusively on the healthcare industry, today announced a partnership and investment in Colorescience, Inc. (“Colorescience” or the “Company”). Terms of the transaction were not disclosed. Founded on a science-first approach to skincare and sun protection, Colorescience is best known for its mineral-based, clinically validated products […]
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
BASEL, Switzerland – January 16, 2026 – Nouscom, a clinical-stage biotech company developing next-generation immunotherapies to treat cancer at all stages, from early cancer interception to late-stage metastatic disease, today announced that results from its Phase 1b/2 clinical trial of NOUS-209 in Lynch Syndrome (LS) carriers have been published in Nature Medicine (D’Alise et al). Publication […]
IntelyCare Acquires CareRev to Create Comprehensive Workforce Staffing Platform for Health Systems
BOSTON, Jan. 8, 2026 /PRNewswire/ — IntelyCare, a leading technology-enabled healthcare staffing platform, today announced the acquisition of CareRev, the on-demand workforce platform purpose-built for acute care. The acquisition brings together two of the industry’s most experienced operators in healthcare workforce management, creating one of the most comprehensive clinical labor solutions in the market. The acquisition positions the combined […]
Healthcare Investing in 2025: Discipline Returned—and the Five Forces Shaping 2026
2025 marked a clear inflection point for healthcare investing—not because capital fully returned, but because discipline did. Liquidity remained constrained, fundraising became more selective, and exit pathways narrowed, forcing both investors and operators to adapt. As a result, healthcare companies are now being built, financed, and evaluated under a far more rigorous set of expectations […]
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
SAN CARLOS, Calif.–(BUSINESS WIRE)–Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class myeloid cell engager therapeutics, announced today that it has entered into a strategic collaboration with Sanofi (NASDAQ: SNY) for the discovery and development of a next-generation B-cell depleting therapy for the treatment of various autoimmune diseases. The new agreement builds on the […]
GSK spins out corporate VC fund focused on bioelectronic tech
GSK has offloaded a corporate venture unit that invests in bioelectronic startups working on neuromodulation, wearables, implanted devices and other technology, Endpoints News has learned. The VC unit, Action Potential Venture Capital (APVC), launched with $50 million from GSK in 2013, when it made its first investment in SetPoint Medical, creator of an implantable device […]
Carrick Therapeutics Announces Positive Results from Phase 2 Randomized Trial of Samuraciclib in Combination with Fulvestrant in Patients with Hormone Receptor Positive, HER2 Negative Advanced Breast Cancer
BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — Carrick Therapeutics Inc., an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced positive results from the Phase 2 SUMIT-BC clinical trial evaluating samuraciclib in combination with fulvestrant in patients with second-line advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) […]